Literature DB >> 35444301

Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation.

Gregory B Lim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35444301     DOI： 10.1038/s41569-022-00714-9

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Authors:  Jonathan P Piccini; Valeria Caso; Stuart J Connolly; Keith A A Fox; Jonas Oldgren; W Schuyler Jones; Diana A Gorog; Václav Durdil; Thomas Viethen; Christoph Neumann; Hardi Mundl; Manesh R Patel
Journal:  Lancet       Date:  2022-04-03       Impact factor: 79.321
  1 in total
  1 in total

Review 1.  HIF in Gastric Cancer: Regulation and Therapeutic Target.

Authors:  Mengqing Li; Guan Li; Xiaodong Yang; Weihua Yin; Guoqing Lv; Shubin Wang
Journal:  Molecules       Date:  2022-07-31       Impact factor: 4.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.